These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 30296945)

  • 1. Should anti-EGFR mAbs be discontinued for conversion surgery in untreated right-sided metastatic colorectal cancer? A systematic review and meta-analysis.
    Chen D; Zhang X; Gao G; Shen L; Xie J; Qian X; Wang H
    World J Surg Oncol; 2018 Oct; 16(1):200. PubMed ID: 30296945
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FOLFOX plus anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) is an effective first-line treatment for patients with RAS-wild left-sided metastatic colorectal cancer: A meta-analysis.
    Chen D; Li L; Zhang X; Gao G; Shen L; Hu J; Yang M; Liu B; Qian X
    Medicine (Baltimore); 2018 Mar; 97(10):e0097. PubMed ID: 29517682
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials.
    Arnold D; Lueza B; Douillard JY; Peeters M; Lenz HJ; Venook A; Heinemann V; Van Cutsem E; Pignon JP; Tabernero J; Cervantes A; Ciardiello F
    Ann Oncol; 2017 Aug; 28(8):1713-1729. PubMed ID: 28407110
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First-line anti-EGFR monoclonal antibodies in panRAS wild-type metastatic colorectal cancer: A systematic review and meta-analysis.
    Pietrantonio F; Cremolini C; Petrelli F; Di Bartolomeo M; Loupakis F; Maggi C; Antoniotti C; de Braud F; Falcone A; Iacovelli R
    Crit Rev Oncol Hematol; 2015 Oct; 96(1):156-66. PubMed ID: 26088456
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemotherapy With or Without Anti-EGFR Agents in Left- and Right-Sided Metastatic Colorectal Cancer: An Updated Meta-Analysis.
    Wang ZX; Wu HX; He MM; Wang YN; Luo HY; Ding PR; Xie D; Chen G; Li YH; Wang F; Xu RH
    J Natl Compr Canc Netw; 2019 Jul; 17(7):805-811. PubMed ID: 31319395
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer.
    Rowland A; Dias MM; Wiese MD; Kichenadasse G; McKinnon RA; Karapetis CS; Sorich MJ
    Br J Cancer; 2015 Jun; 112(12):1888-94. PubMed ID: 25989278
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Meta-analysis comparing the efficacy of anti-EGFR monoclonal antibody therapy between KRAS G13D and other KRAS mutant metastatic colorectal cancer tumours.
    Rowland A; Dias MM; Wiese MD; Kichenadasse G; McKinnon RA; Karapetis CS; Sorich MJ
    Eur J Cancer; 2016 Mar; 55():122-30. PubMed ID: 26812186
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Primary tumor site and anti-EGFR monoclonal antibody benefit in metastatic colorectal cancer: a meta-analysis.
    Li D; Fu Q; Li M; Li J; Yin C; Zhao J; Li F
    Future Oncol; 2017 May; 13(12):1115-1127. PubMed ID: 28110551
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Primary tumour side as a driver for treatment choice in RAS wild-type metastatic colorectal cancer patients: a systematic review and pooled analysis of randomised trials.
    Rossini D; Boccaccino A; Carullo M; Antoniotti C; Dima G; Ciracì P; Marmorino F; Moretto R; Masi G; Cremolini C
    Eur J Cancer; 2023 May; 184():106-116. PubMed ID: 36913832
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of primary tumor sidedness and sex on prognosis and anti-epidermal growth factor receptor antibody efficacy in BRAF-mutant metastatic colorectal cancer: a pooled analysis of AIO studies FIRE-1, CIOX, FIRE-3, XELAVIRI, and VOLFI.
    Alig AHS; Modest DP; Stintzing S; Heinrich K; Geissler M; Fischer von Weikersthal L; Decker T; Vehling-Kaiser U; Held S; Moosmann N; Stahler A; Tannapfel A; Giessen-Jung C; Jung A; Weiss L; Heinemann V
    ESMO Open; 2024 Sep; 9(9):103677. PubMed ID: 39173562
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does the Chemotherapy Backbone Impact on the Efficacy of Targeted Agents in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis of the Literature.
    Chan DL; Pavlakis N; Shapiro J; Price TJ; Karapetis CS; Tebbutt NC; Segelov E
    PLoS One; 2015; 10(8):e0135599. PubMed ID: 26275292
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review.
    Tol J; Punt CJ
    Clin Ther; 2010 Mar; 32(3):437-53. PubMed ID: 20399983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The relevance of primary tumour location in patients with metastatic colorectal cancer: A meta-analysis of first-line clinical trials.
    Holch JW; Ricard I; Stintzing S; Modest DP; Heinemann V
    Eur J Cancer; 2017 Jan; 70():87-98. PubMed ID: 27907852
    [TBL] [Abstract][Full Text] [Related]  

  • 14. On-treatment markers as predictors to guide anti-EGFR MoAb treatment in metastatic colorectal cancer: a systematic review with meta-analysis.
    Hu J; Zhang Z; Zheng R; Cheng L; Yang M; Li L; Liu B; Qian X
    Cancer Chemother Pharmacol; 2017 Feb; 79(2):275-285. PubMed ID: 27878357
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sidedness and TP53 mutations impact OS in anti-EGFR but not anti-VEGF treated mCRC - an analysis of the KRAS registry of the AGMT (Arbeitsgemeinschaft Medikamentöse Tumortherapie).
    Huemer F; Thaler J; Piringer G; Hackl H; Pleyer L; Hufnagl C; Weiss L; Greil R
    BMC Cancer; 2018 Jan; 18(1):11. PubMed ID: 29298682
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A meta-analysis of efficacy and safety data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in adult patients with RAS wild-type metastatic colorectal cancer by sidedness.
    Yoshino T; Hooda N; Younan D; Muro K; Shitara K; Heinemann V; O'neil BH; Herrero FR; Peeters M; Soeda J; Suh M; Reichert H; Mezzi K; Fryzek J; Chia V; Rehn M; Stintzing S
    Eur J Cancer; 2024 May; 202():113975. PubMed ID: 38442645
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment outcome comparisons of first-line targeted therapy in patients with KRAS wild-type metastatic colorectal cancer: A nationwide database study.
    Liang YH; Chen KH; Shao YY
    Cancer Med; 2023 Jul; 12(14):15176-15186. PubMed ID: 37325970
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A study-level meta-analysis of efficacy data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in patients with RAS wild-type metastatic colorectal cancer.
    Heinemann V; Rivera F; O'Neil BH; Stintzing S; Koukakis R; Terwey JH; Douillard JY
    Eur J Cancer; 2016 Nov; 67():11-20. PubMed ID: 27592068
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiepidermal growth factor receptor monoclonal antibody improves survival outcomes in the treatment of patients with metastatic colorectal cancer.
    Wang L; Chen X; Li W; Sheng Z
    Anticancer Drugs; 2012 Feb; 23(2):155-60. PubMed ID: 21955998
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemotherapy plus bevacizumab as an optimal first-line therapeutic treatment for patients with right-sided metastatic colon cancer: a meta-analysis of first-line clinical trials.
    You XH; Jiang YH; Fang Z; Sun F; Li Y; Wang W; Xia ZJ; Wang XZ; Ying HQ
    ESMO Open; 2020 Mar; 4(Suppl 2):. PubMed ID: 32132090
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.